| Name | Title | Contact Details |
|---|
IQUW is a global specialty (re) insurer at Lloyds (syndicate 1856), underwriting complex risks and developing a new way to combine data, intelligent automation and human expertise to make smart decisions, fast. Led by a team of expert underwriters, we underwrite a diverse, multi-line product portfolio including Cargo, Cyber, Delegated Authority Property, D&F Property, D&O, Energy, Financial Institutions, Marine and Energy Liability, Political Violence, Terrorism and War, Property Treaty and Specialty Reinsurance. And because we are a Lloyds syndicate, all our policies come with an A+ rating from Lloyds. To connect with a member of the IQUW team, visit IQUW.com or to visit, you can find us at our HQ in 30 Fenchurch Street, London or at Box 64, 137 and 221 at Lloyds.
MFR Consultants, Inc. (MFR), a full-service management consulting firm headquartered in Philadelphia, PA, has provided end-to-end solutions in the areas of business analysis, information technology, project management and information governance for over 30 years.
Del Peterson & Associates was founded in 1972 by Del Peterson. During the early years we focused our efforts in the Fertilizer & Grain Industries and set the standard for professional onsite auctions in these respective fields. Since that time, Del has retired and his son, Steve Peterson, is now the President/CEO of the business. Del Peterson & Associates Auctioneers is dedicated to making your Online Auction experience the best possible. We specialize in selling equipment and facilities through our public Online Auction Service. This is quickly becoming the industry leader for buyers and sellers to get together to liquidate and expand their businesses. WHAT WE DO DPA Auctions is dedicated to making your Online Auction experience the best possible. We specialize in selling equipment and facilities through our public Online Auction Service. This is quickly becoming the industry leader for buyers and sellers to get together to liquidate and expand their businesses. We strive to maintain the true auction experience at the convenience of selling and bidding over the internet. We provide one of the easiest auction buying platforms. Our Live Auction Board provides the feel of an onsite auction with a dynamic clock, bidding extension time and the comfort and convenience of bidding from you own computer, tablet or smart phone. We have a multi-faceted national marketing program that has proven to be very effective in targeting clients across the United States. We have an experienced sales staff and provide additional marketing support through our website, sale bills, and advertising in respected regional and national publications. Our team of professionals is hard-working, honest, and reliable. Please consider how we can assist you in maximizing the value of the assets you desire to sell and/or provide you excellent values for the equipment and vehicles you wish to purchase. Put our 40 years of experience to work for you with our Selling Made Simple strategy!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.